Hemosiderosis overview

Jump to navigation Jump to search

Hemosiderosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemosiderosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemosiderosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemosiderosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemosiderosis overview

CDC on Hemosiderosis overview

Hemosiderosis overview in the news

Blogs on Hemosiderosis overview

Directions to Hospitals Treating Hemosiderosis

Risk calculators and risk factors for Hemosiderosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hemosiderosis is a condition whenever there is an overload of iron which results in the deposition of hemosiderin in many organs and tissues. Hemosiderosis occurs in the setting of genetic disorders (ie hemochromatosis occurs due to excessive iron absorption), transfusional, abnormal clearance/use, increase absorption, abnormal hepcidin, hemolytic anemia, or homeotropic parasites. Although hemosiderosis implies iron overload without tissue damage, often an early stage of iron accumulation, there are three types of hemosiderosis: Transfusion hemosiderosis, Idiopathic pulmonary hemosiderosis, Transfusional diabetes. Idiopathic pulmonary hemosiderosis (IPH) is a rare disease of unknown etiology characterized by repeated episodes of a diffuse alveolar hemorrhage which cause periodic attack of tachycardia, pyrexia, pallor, fatigue, cyanosis, increasing dyspnea, signs of congestive cardiac failure, severe anamia and hemoptysis. Over the time, It can lead to multiple respiratory complications and permanent lung damage. It is not familial and is found primarily in children from a few months to 16 years of age and rarely be seen in adults.[1] [2]

Historical Perspective

  • IPH was first described as "brown lung induration" by Rudolf Virchow in 1864 in patients after their death.
  • The findings were first to the clinical symptoms by Wilhelm Ceelen gave a more detailed description of the condition after autopsies revealed large amounts of hemosiderin in 2 children in 1931.
  • In 1944, the antemortem diagnosis was made by Waldenstrom

Classification

  • IPH may be grouped into three categories based on disease characteristic:
  • Group 1 pulmonary hemosiderosis involves PH with circulating anti-GMB antibodies.
  • Group 2 pulmonary hemosiderosis involves PH with an immune complex disease such as systemic lupus erythematosus, SLE.
  • Group 3 pulmonary hemosiderosis involves no demonstrable immune system involvement.

Pathophysiology

The pathogenesis of hemosiderosis is characterized by Iron deposition into tissues due to: Genetic (ie hemochromatosis), Transfusional, Abnormal clearance/use, Increase absorption, Abnormal Hepcidin, Hemolytic anemia, Hemotropic parasites.

Causes

  • There are no established causes for IPH, but it is likely to be multifactorial
  • Possible associations include toxic insecticides (based on epidemiological studies in rural Greece), premature birth, and fungal toxin( toxigenic fungus Stachybotrys atra) exposure.

Differentiating IPH from other Diseases

  • IPH must be differentiated from other diseases that cause alveolar hemorrhage, such as those include infectious etiologies( ARDS, streptococcus pneumoniae, staphylococcus aureus, and legionella, influenza A and pneumocystis jirovecii), rheumatic disease such as systemic lupus erythematosus, antiphospholipid antibody syndrome, Goodpasture disease, microscopic, and granulomatous polyangiitis, and mixed cryoglobulinemias, drug-induced injury in medications such as medication such as amiodarone, nitrofurantoin, and infliximab. Penicillamine, thromboembolic disease, bleeding disorders, and neoplasms

Epidemiology and Demographics

  • The prevalence and incidence of IPH are relatively unknown because of the rare nature.

Age

  • IPH is more commonly observed among children. ( approximately 80% of cases are seen in children who are diagnosed in the first decade of life.)
  • 205 of cases are adult-onset IPH.

Gender

  • IPH affects males and females equally in childhood-onset IPH
  • Adult-onset IPH are almost twice as many males as females.
  • Males are more commonly affected with IPH than females in adult-onset IPH.

Race

  • There is no racial predilection for IPH.

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • Early clinical features vary from an acute onset illness with hemoptysis and dyspnea to a chronic cough and dyspnea to repetitive hemoptysis with fatigue, anemia, and slowly progressive dyspnea.
  • Common complications of IPH include Iron deficiency anemia and pulmonary fibrosis.
  • Prognosis is generally variable, and the mean survival rate of patients with IPH is 2.5 to 5 years after diagnosis. Deaths can occur from acute massive hemorrhage or after progressive pulmonary insufficiency and right heart failure.

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References

  1. Chen XY, Sun JM, Huang XJ (November 2017). "Idiopathic pulmonary hemosiderosis in adults: review of cases reported in the latest 15 years". Clin Respir J. 11 (6): 677–681. doi:10.1111/crj.12440. PMID 26692115.
  2. McLETCHIE NG, COLPITTS G (August 1949). "Essential brown induration of the lungs; idiopathic pulmonary haemosiderosis". Can Med Assoc J. 61 (2): 129–33. PMC 1591635. PMID 18147236.

Template:WH Template:WS